Pharma Capital
EPIC: MXCT
Market: AIM
52-week High/Low: 305.00p / 83.00p
Sector: Pharma & Biotech
Market Cap: 107.76M
Website: www.maxcyte.com

MaxCyte is a leader in cell transfection, bringing to market its patented flow electroporation technology. MaxCyte is focused in applying its significant capabilities in the discovery, development, and manufacturing of virtually all classes of innovative therapeutics targeting a broad range of chronic and acute diseases. MaxCyte's customers and partners utilize its technologies in the development and commercialization of cell-based therapies in regenerative medicine and active cell immunotherapies and in the discovery and development of protein drugs, monoclonal antibodies, vaccines, and small molecule drugs. This clinical-grade cell loading technology is fully developed and well validated and has received Master File designation with the CBER Division of the U.S. FDA, has been cleared by NIH's RAC and Health Canada, and is commercialized in Japan. Considerable energy is devoted to R&D on new applications. These efforts have lead to the expanded application of our technology in pharmaceutical and biotherapeutic drug discovery pipelines. Our instrumentation is currently placed in most of the major global pharmaceutical companies and is used for high throughput/high content screening and preclinical protein production. MaxCyte's technology uniquely fulfills the needs for high quality, fully scalable cell modification in both the clinical and R&D arenas.

MAXCYTE INFORMATION AND ARTICLES FOUND HERE ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL

MaxCyte

www.maxcyte.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in MaxCyte

MaxCyte Snapshot

MaxCyte is a leader in cell transfection, bringing to market its patented flow electroporation technology. MaxCyte is focused in applying its significant capabilities in the discovery, development, and manufacturing of virtually all classes of innovative therapeutics targeting a broad range of chronic and acute diseases. MaxCyte's customers and partners utilize its technologies in the development and commercialization of cell-based therapies in regenerative medicine and active cell immunotherapies and in the discovery and development of protein drugs, monoclonal antibodies, vaccines, and small molecule drugs. This clinical-grade cell loading technology is fully developed and well validated and has received Master File designation with the CBER Division of the U.S. FDA, has been cleared by NIH's RAC and Health Canada, and is commercialized in Japan. Considerable energy is devoted to R&D on new applications. These efforts have lead to the expanded application of our technology in pharmaceutical and biotherapeutic drug discovery pipelines. Our instrumentation is currently placed in most of the major global pharmaceutical companies and is used for high throughput/high content screening and preclinical protein production. MaxCyte's technology uniquely fulfills the needs for high quality, fully scalable cell modification in both the clinical and R&D arenas.

MaxCyte's technology is protected by U.S. patents issued and allowed, with over 40 U.S. and international pending patents.

MaxCyte's History

MaxCyte was founded in 1999 to commercialize flow electroporation technology from the CBR Institute for Biomedical Research in Boston, Massachusetts. This technology was initially intended for the treatment of ischemic disorders with the initial clinical application of using flow electroporation to load 1 liter of an autologous red blood cell suspension with an alternative hemoglobin oxygen modulator. MaxCyte pursued the red blood cell application as well as investigated the use of the technology for loading a wide range of biologically active molecules into a variety of cell types.

Our scientist have significantly refined flow electroporation and explored many new clinical and commercial applications. Most recently, drawing on its cell therapy expertise, MaxCyte designed the MaxCyte® STX™ Scalable Transfection System for the rapid, scalable and reagent-free (co)transfection of primary cells, stem cells, and cell lines involved in the burgeoning areas of cell-based assays for high throughput and high content screening, preclinical protein production, and small molecule drug discovery.

MaxCyte's Facilities and Resources

MaxCyte occupies a modern facility in Gaithersburg, Maryland, with more than 50% of the facility dedicated to research and development. We have a well-equipped cell and molecular biology laboratory as well as dedicated tissue culture rooms, including bioreactor systems, cell separation, and analysis systems. MaxCyte engineers design, develop, assemble, and manufacture the electroporation instrumentation and cell processing chambers on-site. This ensures timely delivery of precision-quality products to our clients. The Company's scientific team has unparalleled expertise and continues to make significant advances in developing the flexibility and cutting-edge clinical and commercial applications of flow electroporation.

Gain access to MaxCyte’s proprietary, high performance electroporation technology through one of our benchtop transfection instruments or our custom Insourcing services.  MaxCyte instruments and services are based on a fully scalable electroporation technology that allows for the transfection of 5E5 cells in seconds, up to 2E11 cells in less than 30 minutes.

Let us meet your cell production needs:  MaxCyte STX for 5E5 to 1E10 capacity, MaxCyte VLX for up to 2E11 cells or the MaxCyte GT for cell therapy applications.

Have short term transfection needs or require increased capacity? Let our transfection experts come to your lab and perform the cell transfections you need with our onsite services!

MaxCyte Instrumentation
   MaxCyte STX ®
   MaxCyte VLX ®
   MaxCyte GT ®


Transfection Insourcing Services
Processing Assemblies
Quality Systems

Applications

MaxCyte electroporation is extremely flexible allowing for the introduction of a variety of biomolecules including DNA, RNA, proteins and cellular lysates into a wide range of cell types from cell lines and primary cells to patient-isolated cell populations. The dynamic nature of the technology, its scalability, reproducibility and validated safety enable a diverse array of applications ranging from protein production and drug discovery to ex vivo cell therapy.

Drug Discovery

MaxCyte

Increase your lab’s productivity and improve the quantity and quality of your drug candidates using MaxCyte's next generation, high throughput electroporation technology. Rapidly develop assays in more biologically relevant cell types for use in High Throughput Screening (HTS), High Content Screening (HCS), and other cell-based assays. Enjoy the flexibility of transfecting Any Cell, with Any Molecule, at Any Scale.

For more information, please click here

Protein Production

MaxCyte

 

No need to use specific expression constructs, adapted cell lines, specialized reagents or media additives with MaxCyte electroporation! Rapidly produce from low milligram to multi-gram quantities of antibodies, recombinant proteins to production of vaccines, viral vectors and virus-like particle (VLPs) from a single transfection. MaxCyte transient transfection has become a practical solution to the time, labor and cost challenges faced when relying exclusively on stable cell lines or lower throughput transfection reagents. Enjoy the ultimate in production system flexibility without sacrificing performance.

For more information, please click here

 

Cell Therapy

MaxCyte

Cell loading technologies are fundamental to modify the biological function of cells for cell-based therapeutics and gene therapy applications. The cell processing MaxCyte GT overcomes existing obstacles to cell therapy development with its high-volume, rapid and inherently safe technology that loads diverse cell types with nearly any molecule. For both autologous and allogeneic therapies, the MaxCyte GT can load cells to manipulate functionality; for example, delaying differentiation in stem cells, directing cells towards a desired pathway, producing a protein or eliciting/amplifying an immune response. The MaxCyte GT has received Master File designation with the CBER Division of the U.S. FDA and has been cleared by NIH's RAC and Health Canada.

 For more information, please click here

Stark Thompson, PhD - Non-executive Chairman

Dr. Thompson joined the DuPont Company in 1967 and assumed business management responsibility for the global Clinical Systems Division, a position he held until he left DuPont in 1988. From 1988 until 2000, Dr. Thompson was appointed President, CEO and board member of Life Technologies, Inc. (LTI; NASDAQ: LTEK) ("LTI"). Between 1988 and 2000, LTI grew to become the leading developer, manufacturer and supplier, worldwide, of products and services for life science researchers and companies using biotechnology to produce therapeutics. Dr. Thompson retired from LTI after its takeover in November 2000.

Dr. Thompson has served on the board of directors of ATTO Biosciences; was board chair of Gene Logic, Inc. and was a board member of Ore Pharmaceutical Holdings, Inc. (NASDAQ: ORXE). He was on the board of Luminex Corporation (NASDAQ: LMNX) from 2005 to June 2009 and was a member of the board of Naurex, Inc. Dr. Thompson received his BS degree from Muskingum University, and his MSc and PhD in Physiological Chemistry from Ohio State.

Doug Doerfler - President and Chief Executive Officer

Mr. Doerfler has over 30 years' experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was a founder of MaxCyte in July 1998. Prior to joining MaxCyte, Mr. Doerfler held senior corporate development and operating responsibilities for a privately owned biotechnology holding company. He was President, Chief Executive Officer and a director of Immunicon Corporation, a cell-based therapy and diagnostics company. Mr. Doerfler also held various executive positions with LTI that included leading its global businesses, mergers and acquisitions and its IPO. Mr. Doerfler plays an active role as an advocate for the life sciences industry. He is Chair of the Tech Council of Maryland and serves on the Executive Committees of the Alliance for Regenerative Medicine and the Biotechnology Industry Organization ("BIO"), and Co-Chairs BIO's Capital Formation Committee. Mr. Doerfler received his B.S. in finance from the University of Baltimore School of Business, and holds a certificate in Industrial Relations.

Ron Holtz – Chief Financial Officer

Mr. Holtz serves as MaxCyte's Chief Financial Officer, having joined the Company in 2005. During his career, Mr. Holtz has been Chief Financial Officer of both public and private companies and has raised more than $100m in debt and equity capital. Prior to joining MaxCyte, Mr. Holtz was Chief Financial Officer of B2eMarkets, a privately held software solutions company targeting Global 1000 companies. Mr. Holtz also served as Vice President and Chief Financial Officer of RWD Technologies ("RWD"), a leading information technology and performance improvement consulting firm, where he led RWD's initial public offering and was responsible for finance, acquisitions, business management and analyst/investor relations. Prior to this, Mr. Holtz was a manager in Ernst & Young LLP's Financial Advisory Services Group. He earned a Master's of Business Administration in finance from the University of Maryland, a Bachelor's of Science degree in mathematics from the University of Wisconsin and is a Certified Public Accountant.

Will Brooke – Non-executive Director

Mr. Brooke is Executive Vice President and a director of Harbert Management Corporation ("HMC"), which he co-founded in 1993. With approximately $4 billion under management, HMC sponsors and co-invests in alternative asset strategies worldwide. Mr. Brooke organized and led one of HMC's investment strategies, Harbert Venture Partners, for over a decade when the firm raised three venture capital funds and he lead numerous healthcare and biotech investments for the funds. Mr. Brooke has been advising and investing in early stage and growth companies for more than 20 years, and served on the boards of numerous pharmaceuticals and medical equipment companies, including nContact Corporation, Aldagen Corporation, Innovative Biosensors, Inc., NovaMin Technologies, Inc., Optimal Readings Services Group, Inc., Atherotech, Inc. and Emageon Corporation. Mr. Brooke has also served as HMC's General Counsel, its Chief Operating Officer, and as chairman of its Real Estate Services subsidiary. Prior to joining HMC, Mr. Brooke practiced law for a decade, during which he organized and served as Managing Partner of a commercial law firm. Mr. Brooke holds degrees in law (J.D.) and Business Management (B.S.), each from the University of Alabama.

Stan Erck – Non-executive Director

Mr. Erck, President and CEO, and director of Novavax Corporation, applies his 25 years of management experience in the healthcare and biotechnology industry (Baxter International, Procept, Integrated Genetics, and Iomai) to shepherd the development and commercialization of Novavax Technology. In addition to successfully negotiating major alliances with pharmaceutical and biotechnology companies and bringing products into clinical trials, as CEO he has managed the process of developing companies from private funding through to IPO. Mr. Erck received his B.S. from the University of Illinois and an M.B.A. from the University of Chicago.

Art Mandell – Non-executive Director

Mr. Mandell is a senior executive in the health care industry with over 30 years of experience running companies, executing large corporate and business development deals in both the pharmaceutical and biotechnology sectors, and developing and commercializing a number of products. Mr. Mandell served as President and Chief Operating Officer of Prestwick Pharmaceuticals, Inc. ("Prestwick"). Prior to Prestwick, Mr. Mandell was President, Chief Executive Officer, and a director of Cellective Therapeutics, Inc. ("Cellective"), a monoclonal antibody company developing therapeutic products for autoimmune and oncology diseases. Under his leadership, Cellective was acquired by Astra Zeneca/MedImmune Inc. Before Cellective, Mr. Mandell served as President, Chief Executive Officer, and director of Stemron Corporation, a therapeutic stem cell start up company in Gaithersburg, Maryland and prior to joining Stemron Corporation, he served as Senior Vice President and Chief Business Officer of Human Genome Sciences, Inc. ("HGS"), a biotechnology leader in Gaithersburg, Maryland. Mr. Mandell began his healthcare career at Syntex Pharmaceutical Corporation, where he had profit and loss responsibility for all subsidiaries in the Pacific Rim, Canada and Mexico.

John Johnston – Proposed Non-executive Director

Mr. Johnston is currently Non-executive director of Action Hotels plc, Flowgroup plc and Midatech Pharma plc, Non-executive chairman of Constellation Healthcare Technologies Inc., and prior to this was managing director of Institutional Sales at Nomura Code. He was previously director of Sales and Trading at Seymour Pierce from 2008 to 2011. In 2003, Mr. Johnston founded Revera Asset Management, where he oversaw an investment trust, a unit trust and a hedge fund, which he ran until 2007. From 1992 to 1997, Mr. Johnston was Head of Small Companies at Scottish Amicable, before spending a year at Ivory and Sime, again as Head of Small Companies from 1997 to 1998. He joined Legg Mason Investors for three years as director of Small Companies Technology and Venture Capital Trusts, from 2000 to 2003, having previously spent two years as Head of Small Companies with Murray Johnstone. Mr. Johnston began his investment career at the Royal Bank of Scotland in 1981, working in the Trustee and Investment department, before moving to General Accident in 1985, holding the position of Head of Retail Funds before his move to Scottish Amicable.

Senior Management

Madhusudan Viswanath Peshwa, PhD, Chief Scientific Officer, Executive Vice President, Cellular Therapies

Dr. Peshwa currently serves as Chief Scientific Officer at MaxCyte, having joined the Company in 2005. He was Executive Vice President for Research and Development at NewNeural, a start-up stem cell therapy company. Previously, Dr. Peshwa served as Vice President of Manufacturing and as Vice President of Process Sciences at Dendreon Corporation (NASDAQ: DNDN), where he was responsible for development, characterization and manufacture of an autologous dendritic cell vaccine product from concept to late Phase III pivotal studies. His expertise is in the areas of design, characterization, scale-up and implementation of processes, and in cGMP systems for the development of engineered cell and tissue products and for biopharmaceuticals production. Dr. Peshwa obtained his PhD in chemical engineering from the University of Minnesota and his BTech in chemical engineering from the Indian Institute of Technology, Kanpur, India. He is a co-author on over 35 scientific publications and is a co-inventor on five, issued or under review, patent applications.

Thomas Michael Ross, Executive Vice President, Global Sales

Mr. Ross serves as MaxCyte's Executive Vice President of Global Sales, having joined the Company in 2014. Mr. Ross has extensive experience in all elements of commercial operations and has over 25 years of successful sales and marketing leadership in the Life Science and Clinical Diagnostics markets. Most recently, Mr. Ross was Senior Vice President of Commercial Operations at OpGen®. Mr. Ross also served as Chief Commercial Officer at Predictive BioScience and Vice President of North America Medical Diagnostics Sales at Qiagen/Digene Corporation. Prior to working at Digene Corporation, Mr. Ross held several senior leadership roles in Manufacturing Operations at LTI and Cambrex.

Debra K. Bowes, Executive Vice President, Business and Strategic Development

Ms. Bowes has more than 25 years’ experience in corporate strategy, licensing and in the creation of partnerships to advance the development and commercialization of biopharmaceutical products, with a main emphasis in oncology. Before joining MaxCyte in 2016, Ms. Bowes was interim President and Chief Executive Officer of CapGenesis Pharma, in Bethesda, MD. Previously, she served as President and Founder of Chevy Chase BioPartners, LLC, a strategic planning consultancy, as well as in leadership positions at CBLI Pharmaceuticals, MedImmune, Amylin Pharmaceuticals, Pfizer, Ligand Pharmaceuticals, Centocor and Hybritech. She also has served as national president of Women in Bio. Ms. Bowes is a Master’s Degree candidate at Johns Hopkins University, and has a BS in cell biology from the University of Cincinnati.

James Brady, Vice President, Technical Applications and Customer Support

Dr. Brady is Vice President of Technical Applications and Customer Support at MaxCyte, Inc. Prior to joining MaxCyte in 2004, Dr. Brady was a Senior Scientist at Genetic Therapy, Inc., a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments for ocular disorders. Previously, he worked at MetaMorphix, Inc. as a Group Leader in the Company’s Transgenic Livestock program, and was a postdoctoral fellow at the National Eye Institute of the National Institutes of Health. Dr. Brady received a Bachelor of Science degree in biology from the College of William and Mary, a Ph.D. in genetics from Indiana University and an MBA from Johns Hopkins University.

Markus J. Hunkeler, Vice President, Marketing

Mr. Hunkeler joined MaxCyte in 2016 as Vice President of Marketing. With over 25 years in life science company leadership positions, Mr. Hunkeler brings a wide variety of product and marketing experiences to MaxCyte. Most recently Mr. Hunkeler managed international sales for ATCC. Prior to that, he was Director of Product Development at Life Technologies Corporation, Senior Director of Marketing at BioReliance and Director of Marketing at Lonza. Mr. Hunkeler has Bachelor and Master of Science degrees in biochemistry and an MBA from the University of Maryland.

MaxCyte, Inc
22 Firstfield Road, Suite 110
Gaithersburg, MD 20878
Tel: (301) 944-1700
Fax :(301) 944-1703
email: [email protected]

MaxCyte, Inc.
BioHub at Alderley Park
Alderley Edge
Cheshire
SK10 4TG

 

MaxCyte has appointed Panmure Gordon to act as nominated adviser and broker to the Company for the purposes of the AIM Rules for Companies.

MaxCyte Timeline

View All

Market Reports Including MXCT

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.